Abbott Biotechnology Ltd.

Abbott Gmbh & Co Kg

Basf Aktiengesellschaft

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Abbvie Biotechnology Ltd

Paul Sakorafas

Boris Labkovsky

Jochen G Salfeld

Zehra Kaymakcalan

Michael White

Tristan J Vaughan

Brian Timothy McGuinness

John A Mankovich

David Schoenhaut

Deborah J Allen

Andrew J Roberts

Alison Jane Wilton

Hendricus R J M Hoogenboom

Geertruida Machteld Veldman

Michael Roguska

Nicholas W Warne

Subhashis Banerjee

Thor Las Holtet

Angela Widom

Daniel Edward Tracey

Elaine Joy Derbyshire

John Gawain Elvin

Sara Carmen

Alexander Robert Duncan

Michael Paskind

Stuart Friedrich

Sarah Leila Du Fou

Stephen Smith

Amy Venturini

Angela Myles

Angela Kantor

Hendricus Renerus Hoogenboom

Hendricus Rjm Hoogenboom

Alison J Wilton

Hendricus R Hoogenboom

Brian T Mcguinness

Boris Labkovksy

Hendricus RJM Hoogenboom

Brian T Mcguiness

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&#x3b1;

Human antibodies that bind human TNF&#x3b1; and methods of using same

Methods of treating disorders using human antibodies that bind human TNF&#x3b1;

Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods for inhibiting the activity of the P40 subunit of human IL-12

Methods for treating rheumatoid arthritis using human antibodies that bind human TNF&#x3b1;

Human antibodies that bind human IL-12

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human IL-12 and methods for producing

Growing community of inventors

Newton Highlands, MA, United States of America

Paul Sakorafas